Scientist I/II, Therapeutic Technologies

Addition Therapeutics•South San Francisco, CA

10h•Onsite

About The Position

Addition Therapeutics leads in biotechnology innovation, developing next-generation gene therapies through our proprietary PRINT™ (Programmable RNA-guided Integration Technology) platform. PRINT™ revolutionizes genetic medicine by enabling the creation of RNA-only therapeutics that insert genetic elements into specific safe harbor sites within the genome. Based in state-of-the-art labs in South San Francisco, we are a Series A-stage company with programs targeting both rare and common diseases. We seek a Scientist I or II to join our Therapeutic Technologies team, specializing in GPCR pharmacology and disease assay development. This hands-on research role involves building cell-based and in vivo assays to evaluate PRINT-delivered payloads in disease-relevant contexts, from early discovery to IND-enabling studies. The ideal candidate has extensive experience in GPCR biology—receptor signaling, ligand pharmacology, internalization, and the downstream functional consequences of receptor activation. You can translate this expertise into rigorous assays that address real therapeutic questions, particularly with metabolic-disease-relevant GPCRs (e.g., GLP-1R, GIPR, glucagon receptor, MC4R, and related cardiometabolic targets). You will collaborate closely with our RNA sciences and protein engineering teams to define and achieve program-specific success metrics.

Requirements

Ph.D. in biochemistry, pharmacology, cell biology, or a closely related field (relevant industry experience may substitute for a Ph.D.)
Hands-on experience with GPCR pharmacology assays—receptor signaling, internalization, cAMP/arrestin assays, or similar.
Strong cell culture skills: experience with primary cells and/or iPSC-derived models.
Proficiency with standard molecular/biochemical assay platforms: ELISA, ddPCR, qPCR, Western blot, flow cytometry.
Ability to independently design experiments, troubleshoot, and interpret data with minimal supervision.
Clear and organized scientific communicator, comfortable presenting data to cross-functional audiences.

Nice To Haves

Experience with obesity- or metabolic-disease-relevant GPCRs and the pharmacology of incretin-class or other anti-obesity therapeutics.
Familiarity with metabolic phenotyping endpoints (body composition, energy expenditure, glucose/insulin tolerance, lipid profiling) and disease-relevant tissue biology (adipose, liver, gut, hypothalamus).
Experience with secreted protein biology or hormone pharmacology in a disease context.
Familiarity with HTS or automated liquid handling platforms.
Experience with gene therapy, mRNA, or RNA-based therapeutic modalities.
Exposure to NHP or translational PK/PD study design.

Responsibilities

Designing, developing, and validating cell-based pharmacology assays for GPCR targets, including cAMP, beta-arrestin recruitment, receptor internalization, and pathway-selective (biased agonism) readouts to differentiate construct performance across combinatorial screening.
Utilizing deep mechanistic knowledge in GPCR pharmacology to guide candidate prioritization, model selection, and assay design, providing informed scientific judgment at critical decision points.
Executing in vitro assays with primary cells and disease-relevant cell lines to characterize PRINT-delivered payload activity, including adipocytes, hepatocytes, pancreatic, and neuronal models.
Supporting in vivo studies in rodent disease models, including study design and pharmacodynamic endpoint analysis.
Applying quantitative molecular techniques (ddPCR, qPCR, ELISA, Western blot, flow cytometry) to characterize transgene expression, protein secretion, and PD endpoints.
Working with HTS infrastructure and liquid handling automation to scale assay throughput as programs expand.
Collaborating with computational biology and protein engineering teams to connect payload design with functional readouts.
Contributing to data packages for IND-enabling studies, partnership diligence, and investor milestones.